Abstract Number: 2527 • ACR Convergence 2025
Safety Profile and Impaired Humoral Response to the Recombinant Herpes Zoster Vaccine in Behçet’s Syndrome Patients under Immunosuppression: a Prospective, Randomized, Placebo-Controlled Trial
Background/Purpose: Although rare, new-onset Behçet’s syndrome (BS) and disease flares have been reported following vaccination. In this context, the recommendation of the Recombinant Herpes Zoster…Abstract Number: 1192 • ACR Convergence 2025
Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine
Background/Purpose: Although herpes zoster vaccination has been evaluated in immunocompromised populations, studies assessing vaccine immunogenicity and safety in idiopathic inflammatory myopathies (IIM) are restricted to…Abstract Number: 0083 • ACR Convergence 2025
Confirmatory Factor Analysis of the Plutchik Suicide Risk Scale in Patients with Rheumatoid Arthritis
Background/Purpose: Prevalence of depression in RA patients ranging from 10% to 25%, making it the most common psychiatric disorder in this population. The Plutchik Suicide…Abstract Number: 2226 • ACR Convergence 2025
Factors Associated with Contraceptive Counseling by Rheumatologists for Reproductive-Aged Female Patients Prescribed Teratogenic Medications
Background/Purpose: Guidelines advise rheumatologists to provide contraceptive counseling for all patients with pregnancy potential prescribed teratogenic medications, however, adherence is inconsistent. We assessed the frequency…Abstract Number: 1157 • ACR Convergence 2025
Safety and Tolerability of a Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Prospective Longitudinal Study over 12 Months
Background/Purpose: Herpes zoster (HZ) is common among older adults, with a lifetime risk of 25%. The risk is particularly increased in individuals with immunosuppression such…Abstract Number: 0023 • ACR Convergence 2025
Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Background/Purpose: Hydroxychloroquine (HCQ) is routinely prescribed for treatment of systemic lupus erythematosus (SLE) due to its efficacy at decreasing disease activity/SLE flares and strong benefit:risk…Abstract Number: 2195 • ACR Convergence 2025
Enhancing MTX and LEF Safety for Immunosuppressed Women of Childbearing Age with Rheumatic Diseases
Background/Purpose: The rates of contraceptive counseling and treatment in immunosuppressed women of childbearing age remain low in the United States, despite ACR's Reproductive Health Guidelines…Abstract Number: 1109 • ACR Convergence 2025
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…Abstract Number: 1982 • ACR Convergence 2025
Bridging the Gap in Underserved Care: A Quality Improvement Initiative to Increase Pneumococcal Vaccination Rates in Immunocompromised Rheumatology Patients
Background/Purpose: Patients with rheumatologic conditions who are on immunosuppressive therapy face an elevated risk of pneumococcal infections, particularly those in medically underserved populations. Per ACR…Abstract Number: 1061 • ACR Convergence 2025
Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN
Background/Purpose: Hepatitis B virus (HBV) screening is insufficiently completed prior to initiation of immunosuppressive therapy nationwide. Various factors including alert fatigue, provider mistakes, non-compliance, and…Abstract Number: 1980 • ACR Convergence 2025
Improving Vaccination Rates in the Rheumatology Clinic
Background/Purpose: Influenza and pneumococcal infection can cause mild to severe illness and potentially lead to serious complications or death. Patients with rheumatic diseases have weakened…Abstract Number: 1034 • ACR Convergence 2025
Healthy Dietary Patterns and Risk of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Background/Purpose: Healthy dietary patterns are associated with many health benefits, including lower cardiovascular disease, mortality, and rheumatoid arthritis (RA) disease activity. Therefore, we aimed to…Abstract Number: 1934 • ACR Convergence 2025
Analysis of the Determinants of Vaccine Acceptance and Hesitancy in Germany: A Mixed-Methods Approach Incorporating Health Insurance Data and Qualitative Interviews with Patients and Physicians
Background/Purpose: Adequate immunization is essential for patients with inflammatory rheumatic and musculoskeletal diseases (iRMD). Autoimmunity itself and immunotherapy increase the risk of infection independent of…Abstract Number: 1023 • ACR Convergence 2025
Comparative Analysis of Oral Health and Dental Care in Patients With Immune-Mediated and Non-Immune-Mediated Rheumatic Diseases
Background/Purpose: Oral health impairment is common in patients with immune-mediated rheumatic diseases (IMRDs) due to chronic inflammation and immune dysregulation. These complications can worsen systemic…Abstract Number: 1932 • ACR Convergence 2025
Evaluating a Potential Cause of Excess Lung Cancer Mortality in RA: An Analysis of Chest CT Imaging Frequency in RA
Background/Purpose: Recent studies have demonstrated that patients with RA are at an increased risk for the development of lung cancer and lung cancer related death.…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 15
- Next Page »
